• New-hire equity awards granted on Aug. 20, 2026 under Nektar’s 2025 Inducement Plan.
• Stock options cover 25,200 shares; exercise price USD 74.53; eight-year term.
• RSUs total 5,000; options vest over four years with 25% after one year, then monthly; RSUs follow a similar four-year schedule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608281615PR_NEWS_USPR_____SF35891) on August 28, 2026, and is solely responsible for the information contained therein.